Livzon Pharmaceutical repurchases A-shares as part of ongoing program

Livzon Pharmaceutical Group has disclosed its latest share repurchase activity, with the company buying back 128,700 A-shares on September 22, 2025, through the Shenzhen Stock Exchange. The repurchases were executed at prices ranging from RMB 38.56 to RMB 39.02 per share, totaling RMB 4,998,418. All repurchased A-shares are intended for cancellation.

The company's outstanding H-shares remain unchanged at 299,807,117 as of September 22, 2025. This repurchase activity is part of an ongoing buyback program, with numerous A-share repurchases recorded between December 25, 2024, and September 22, 2025. These transactions highlight Livzon Pharmaceutical's strategy to manage its capital structure and enhance shareholder value.

The repurchases align with the company's previously approved authorization, as confirmed on April 24, 2025. All disclosed transactions adhere to the relevant listing rules in Hong Kong and the applicable regulations for A-share repurchases in Shenzhen.